ERO1B

ERO1B (ERO1β) is an ER-resident FAD-dependent sulfhydryl oxidase that drives oxidative protein folding in the secretory pathway, conserved from the essential yeast Ero1p, whose loss causes ER retention of disulfide-stabilized proteins in a reduced, non-native form while leaving disulfide-free maturation intact (PMID:9659914). Mechanistically, ERO1β oxidizes protein disulfide isomerase (PDI) in the ER lumen, which then relays oxidative equivalents to cargo proteins, a flux opposed by cytosolic reduced glutathione to set ER redox balance (PMID:15161913); recombinant ERO1β is roughly twice as active as ERO1α and preferentially engages the a' active site of PDI (PMID:21091435). Its catalytic output is restrained by regulatory disulfide bonds Cys90-Cys130 and Cys95-Cys100, with Cys130 critical to feedback control, and disruption of Cys100 yields a hyperactive enzyme that perturbs ER redox state and induces the UPR (PMID:21091435, PMID:27919037). ERO1β functions as homodimers and as heterodimers with ERO1α and PDI through its active site (PMID:16012172), and is retained in the ER via dynamic covalent interactions with PDI and ERp44, which compete for binding (PMID:16677073). ERO1β is constitutively and selectively expressed in professional secretory cells, notably pancreatic β-cells and gastric chief cells (PMID:16012172), where it serves a cell-type-specific, essential role in proinsulin oxidative folding and glucose homeostasis; its dosage must be fine-tuned, as both loss and overexpression impair insulin biogenesis and β-cell function in vivo (PMID:20308425, PMID:24469402).

1. 1998 High

   Established that the ERO1 family is an essential, dedicated catalyst of ER disulfide bond formation rather than a general folding factor, by showing loss specifically blocks maturation of disulfide-containing proteins.

   Evidence Genetic loss-of-function and overexpression complementation with protein maturation assays in yeast

   PMID:9659914

   Open questions at the time

   • Yeast ortholog only; does not address human ERO1β isoform specialization
   • Direct enzymatic mechanism (FAD chemistry, PDI as proximal substrate) not resolved here
2. 2004 Medium

   Defined the catalytic relay by showing ERO1 oxidizes PDI, which passes oxidizing equivalents to cargo, and that cytosolic GSH counterbalances this flux across compartments.

   Evidence Semipermeable cell assays with PDI redox-state measurements, ERO1α overexpression and GSH addition

   PMID:15161913

   Open questions at the time

   • Largely centered on ERO1α; ERO1β-specific contribution not separately quantified
   • Single lab biochemical system
3. 2005 Medium

   Showed ERO1β assembles into active-site-dependent homo- and heterodimers and is expressed in a cell-type-restricted pattern, linking the enzyme to professional secretory cells.

   Evidence Reciprocal Co-IP, active-site mutagenesis, dimerization assays, and tissue immunohistochemistry

   PMID:16012172

   Open questions at the time

   • Functional consequence of dimerization for catalysis not established
   • Single-lab Co-IP evidence
4. 2006 Medium

   Identified the ER-retention mechanism for ERO1β through covalent interactions with PDI and ERp44, with ERp44 covalent binding essential and PDI/ERp44 competing for ERO1.

   Evidence Co-expression/secretion assays in HeLa cells, Co-IP, KDEL/RDEL retention assays, PDI cysteine mutagenesis

   PMID:16677073

   Open questions at the time

   • Relative in vivo contribution of PDI versus ERp44 to retention unresolved
   • Based on overexpression in non-secretory HeLa cells
5. 2006 Medium

   Mapped FAD-binding-domain residues required for catalytic integrity, separating dimerization/non-covalent PDI binding from disulfide-dependent PDI engagement and revealing misoxidation/aggregation under stress.

   Evidence Site-directed mutagenesis modeled on yeast ero1-1/ero1-2, Co-IP, redox/temperature stress and dimerization assays

   PMID:16822866

   Open questions at the time

   • No structural model of the FAD domain in human ERO1β
   • Single-lab mutagenesis
6. 2010 High

   Demonstrated a non-redundant, cell-type-specific physiological role by showing ERO1β is the predominant β-cell isoform whose loss impairs proinsulin oxidative folding and causes glucose intolerance.

   Evidence Ero1lb knockout mice, proinsulin folding/secretion assays, glucose tolerance tests, epistasis with Ero1l double knockout

   PMID:20308425

   Open questions at the time

   • Molecular basis for β-cell selectivity of ERO1β not explained
   • Residual oxidative folding capacity in knockout implies redundancy not fully defined
7. 2011 High

   Quantified ERO1β as ~2-fold more active than ERO1α with preference for the PDI a' site, and showed its activity is regulated by long-range disulfides but more loosely than ERO1α.

   Evidence In vitro enzymatic assays with recombinant proteins, PDI-family oxidation assays, disulfide mutant analysis

   PMID:21091435

   Open questions at the time

   • Physiological consequence of loose regulation in β-cells not directly tested here
   • Single-lab reconstitution
8. 2014 Medium

   Established that ERO1β dosage must be fine-tuned, since both reduced expression in diabetic models and forced overexpression impair β-cell function via ER stress and reduced insulin content.

   Evidence Diabetic mouse models, β-cell ERO1β overexpression, UPR gene analysis, EM of ER, insulin secretion assays

   PMID:24469402

   Open questions at the time

   • Mechanism coupling ERO1β overactivity to UPR induction not fully resolved
   • Cause of paradoxical downregulation in diabetes unknown
9. 2014 Medium

   Resolved the identity of the regulatory disulfides (Cys90-Cys130, Cys95-Cys100) and showed Cys100 mutation, not the previously proposed Cys262 bond, drives hyperactivity and ER redox perturbation.

   Evidence Cys mutagenesis, alkylation protection in living cells, UPR reporters, molecular modeling

   PMID:27919037

   Open questions at the time

   • No experimental structure of the regulated and hyperactive states
   • Single-lab modeling-based interpretation

• How ERO1β's loose redox regulation is tuned in vivo to the high secretory burden of β-cells, and what determines its cell-type-restricted expression, remain open.
• No experimental structure of human ERO1β
• Transcriptional/regulatory basis of β-cell and chief-cell selectivity unknown
• Quantitative contribution of PDI versus ERp44 to retention in native secretory cells undefined